Buprenorphine Dispensing Rate Maps

Buprenorphine is an FDA-approved evidence-based medication to treat opioid use disorder (OUD) that can be dispensed through retail pharmacies.1 The data in the maps show the geographic distribution in the United States of retail pharmacy-dispensed buprenorphine prescriptions per 100 persons per year from 2019–2022. 2,3,4

Data are displayed as state maps that portray the estimated rate of buprenorphine prescriptions per 100 U.S. residents per year for each of the 50 states and the District of Columbia. Click on a state to reveal its buprenorphine dispensing rate or view the corresponding data table for additional information.

Key Highlights
  • The overall national buprenorphine dispensing rate increased slightly from 2019 to 2022 with the highest rate in 2021 at 4.9 buprenorphine prescriptions dispensed per 100 persons (a total of more than 16 million buprenorphine prescriptions).
  • Buprenorphine dispensing rates varied widely across the country.
    • States with the highest buprenorphine dispensing rates in 2022 per 100 persons include West Virginia (27.2), Vermont (25.5), Kentucky (23.6), and Maine (17.8).
    • States with the lowest buprenorphine dispensing rates in 2022 per 100 persons include Iowa (1.3), Texas (1.4), California (1.6), and Hawaii (1.8).

1 https://www.cdc.gov/opioids/healthcare-professionals/prescribing/opioid-use-disorder.html


2 Source for all dispensing data: IQVIA Xponent 2019–2022. IQVIA Xponent is based on a sample of approximately 56,500 retail (non-hospital) pharmacies, which dispense nearly 93% of all retail prescriptions in the United States. For this database, a prescription is a new or refilled prescription dispensed at a retail pharmacy in the sample and paid for by commercial insurance, Medicaid, Medicare, cash or its equivalent, and other third-party coverage. This database does not include mail-order prescriptions. Geographic location is based on the location of the prescriber. Methadone dispensed through methadone treatment programs is not included in the IQVIA Xponent data.

3 Buprenorphine formulations commonly prescribed for treating pain (Belbuca and Butrans) were excluded.

4 For the calculation of dispensing rates, numerators are the projected total number of buprenorphine prescriptions dispensed annually at the state, county, or national level. Annual resident population denominators were obtained from the U.S. Census Bureau.

Note: data updated October 2023, rates are subject to change with future data updates.

Access the latest guideline, data, and resources